PharmaSource Podcast · Life Science Networks

Markus Sieger Reflects on 25 Years Building Polpharma into Europe’s Generic Manufacturing Leader

·32 min·2 clips
Markus Sieger explains why being a generalist from other industries gives him an edge in transforming pharma.
Markus Zeiger starts by tracing the path that brought him into pharma. He grew up in Switzerland and studied there. Later, he worked in the United States in information technology. With an economics background, he then moved into an investment banking boutique. That job led him to spend about 20 years helping entrepreneurs in emerging markets grow. He says that experience made him a generalist, and it also gave him ideas from other industries that carried over into pharmaceutical work. The conversation frames Polpharma as one of Central and Eastern Europe’s largest pharmaceutical manufacturers. It notes that he has spent 25 years with the company. It also notes that he will step down as CEO on January 1, 2026. After that, he will move to the supervisory board. From there, the discussion shifts to the evolution of generic medicines in Europe. It also looks at what that means for scale, execution, and Polpharma’s place in the market. The interview keeps asking him to unpack how he led and grew Polpharma. He answers in terms of structure, execution, and long-term business development. The show stays focused on practical questions rather than turning him into a legend. Later, the conversation turns to the pressure COVID put on factory teams. Zeiger describes how staff had to keep going while many others stayed home. He says he has a lot of respect for the people who kept working on site. He also says their effort helped save lives. The discussion then moves to the war in Ukraine. He describes the strain caused when people were drawn into military service. He also mentions doctors working in military hospitals. Polpharma responded by donating medication early on. As the system stabilized, the company invested further in the market. It built new brands and supported local teams where it could. Zeiger presents that support as practical, but also as something the company owed the market. The episode then asks whether the war affected supply or demand. He says they did not have a major supply issue there. He also says the business is not as strong as he would like. Even so, he calls the market interesting and growing. The interview ends by returning to the industrial side of pharma. Zeiger points to innovation as the part of the value chain that still surprises and motivates him. He talks about new products, new applications, manufacturing methods, safer use, and more convenient formulations. The closing point is simple: pharma keeps improving in ways meant to help patients live better lives.

As heard by us

A practical, industry-focused look at generics, resilience, and the work of building durable pharma capacity.

Markus Zeiger's conversation presents Polpharma as one of Central and Eastern Europe's largest pharmaceutical manufacturers, while tracing his path from Switzerland to the US and then into investment banking and pharma.

Read the full review in PlayNext →

Why you'd press play

You want the real story behind a Central and Eastern European pharma leader, not a polished leadership reel.

Read the full recommendation in PlayNext →
Listen to the show on